

SEQUENCE LISTING

<110> CELLTECH THERAPEUTICS LIMITED

<120> RECOMBINANT FUSION PROTEINS

<130> P023523WO

<140> PCT/GB99/03979

<141> 1999-11-29

<150> GB9826112.6

<151> 1998-11-27

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cleavage site

<400> 1

Asp Lys Thr His

1

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cleavage site

<400> 2

Asp Arg Ser His

1

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cleavage site

<400> 3

Glu Lys Ser His

1

<210> 4  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: cleavage site

<400> 4  
Asp Lys Ser His  
1

<210> 5  
<211> 118  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: plasmid DNA

<400> 5  
tagtctgcag gtgctgacct gcccgccgtg tccggataaa acccatacca tcgaaggcag 60  
tactagcgat tataaagatg atgatgataa atgatgagga tccaagcttg cggccgcg 118

<210> 6  
<211> 119  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: plasmid DNA

<400> 6  
aattcgggc cgcaagcttg gatactcatc atttatcatc atcatcttta taatcgctag 60  
tactgccttc gatggtatgg gttttatccg gacacggcgg gcaggtcagc acctgcaga 119

<210> 7  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: C-terminus of  
Fab' 40.4 hinge delta inter' heavy chain

<400> 7  
Glu Pro Lys Thr Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala  
1 5 10 15

<210> 8  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: C terminus of  
'Fab 40.4 hinge 1 delta inter Null 2 FLAG' heavy  
chain

<400> 8

Glu Pro Lys Thr Ser Leu Gln Val Leu Thr Cys Pro Pro Cys Asp Lys  
1 5 10 15

Thr His Thr Ile Glu Gly Ser Thr Ser Asp Tyr Lys Asp Asp Asp Asp  
20 25 30

Lys

<210> 9

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Null 2 peptide

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLTATION;

<220>

<221> MOD\_RES

<222> (11)

<223> AMIDATION

<400> 9

Val Glu Pro Lys Thr Ser Leu Gln Val Leu Thr  
1 5 10

<210> 10

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CUT 1 peptide

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLTATION

<220>

<221> MOD\_RES

<222> (11)

<223> AMIDATION

<400> 10

Val Glu Pro Lys Thr Ser Asp Lys Thr His Thr  
1 5 10

<210> 11  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: cleaved CUT 1  
peptide

<220>  
<221> MOD\_RES  
<222> (1)  
<223> ACETYLTATION

<220>  
<221> MOD\_RES  
<222> (8)  
<223> Hyl

<400> 11  
Val Glu Leu Lys Thr Ser Asp Lys  
1 5

<210> 12  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: N terminal  
sequence of cleaved FLAG tail

<400> 12  
Thr His Thr Ile Glu Gly  
1 5

<210> 13  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: FLAG tail  
cleavage product of Null 2 Flag peptide

<400> 13  
Thr His Thr Ile Glu Gly Ser Thr Ser Asp Tyr Lys Asp Asp Asp Asp  
1 5 10 15

Lys

<210> 14

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Null site of  
Null 2 FLAG

<400> 14

Leu Gln Val Leu

1